1256390-39-2

Basic information

• Product Name: (S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]nonane-8-carboxylic acid 2-(4-bromo-phenyl)-2-oxo-ethyl ester
• Synonyms: (S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]nonane-8-carboxylic acid 2-(4-bromo-phenyl)-2-oxo-ethyl ester
• CAS NO: 1256390-39-2
• Molecular Weight: 527.369
• Mol File: 1256390-39-2.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: (S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]nonane-8-carboxylic acid 2-(4-bromo-phenyl)-2-oxo-ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]nonane-8-carboxylic acid 2-(4-bromo-phenyl)-2-oxo-ethyl ester(1256390-39-2)
• EPA Substance Registry System: (S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]nonane-8-carboxylic acid 2-(4-bromo-phenyl)-2-oxo-ethyl ester(1256390-39-2)

Safety Data

• Hazardous Substances Data: 1256390-39-2(Hazardous Substances Data)

Upstream product

• 99-90-1 para-bromoacetophenone 
• 16217-17-7 7-<(phenylmethoxy)carbonyl>-1,4-dioxa-7-azaspiro<4,4>-nonane-8(S)-carboxylic acid methyl ester 
• 16217-15-5 1-benzyloxycarbonyl-4-oxo-L-proline methyl ester 
• 57653-35-7 (2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-benzyl 2-methyl 
• 618-27-9 hydroxy L-proline 
• 66682-58-4 1,4-dioxa-7-azaspiro<4.4>-nonane-8(S)-carboxylic acid methyl ester 
• 1256390-38-1 (S)-7-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-1,4-dioxa-7-azaspiro[4.4]nonane-8-carboxylic acid 
• 99-73-0 para-bromophenacyl bromide 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 72-18-4 L-valine 
• 1272654-95-1 (S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]nonane-8-carboxylic acid methyl ester 
• 1272654-92-8 (S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-4-oxo-pyrrolidine-2-carboxylic acid methyl ester 
• 1272654-89-3 (2S,4R)-4-Hydroxy-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidine-2-carboxylic acid methyl ester 

Downstream Products

• 1433280-22-8 4'-{2-[(S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]non-8-yl]-1H-imidazol-4-yl}-biphenyl-4-carboxylic acid 
• 1256390-26-7 ((S)-1-{(S)-8-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-1,4-dioxa-7-aza-spiro[4.4]nonane-7-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 
• 1433280-02-4 (4'-{2-[(S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]non-8-yl]-1H-imidazol-4-yl}-2-trifluoromethoxy-biphenyl-4-yl)-carbamic acid tert-butyl ester 
• 1399843-64-1 methyl ((S)-3-methyl-1-oxo-1-((S)-8-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)butan-2-yl)carbamate 
• 1256390-26-7 methyl ((S)-1-((S)-8-(5-(4-bromophenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)-3-methyl-1-oxobutan-2-yl)carbamate 

Relevant articles and documents

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.

FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X', Y, Y', A, A',Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.